10 yrs of 'Make in India': Govt eyes $100 bn FDI inflows annually

The "Make in India" initiative has laid a strong foundation for India's industrial growth, positioning the country as a global leader in manufacturing, especially in mobile phones and semiconductors. Below are some achievements

Foreign Direct Investment (FDI) Goals:

• The Indian government aims to increase annual FDI inflows to $100 billion in the coming years, up from the current level of $70-80 billion.
• This aligns with the "Make in India" initiative, a 10-year-old program designed to boost manufacturing, attract foreign investment, and promote indigenous production.

Achievements of "Make in India" (2014-2024):

• Significant improvements in manufacturing infrastructure, defense capabilities, and exports.
• Total FDI inflows over the last 10 years reached $667.4 billion, compared to $304.1 billion in the previous decade (2004-2014).
• FDI equity inflow into the manufacturing sector between 2014-2024 rose by 69%, amounting to $165 billion.

Sectoral Focus and Growth:

• Major sectors attracting FDI include automobiles, telecommunications, and pharmaceuticals.
• India's mobile manufacturing sector witnessed a dramatic rise, with the number of mobile manufacturing units increasing from 2 in 2014 to over 200 by 2024. This led to a 7,500% increase in mobile phone exports, from Rs 1,556 crore to Rs 1.2 trillion.

Production-Linked Incentive (PLI) Scheme:

• By June 2024, the 14 sectors covered under the PLI scheme saw investments totaling Rs 1.32 trillion and production valued at Rs 10.90 trillion.
• The scheme has also generated approximately 850,000 jobs.

Key Investments and Future Focus:

• India’s semiconductor sector is growing rapidly, with investments exceeding Rs 1.5 trillion.
• Five semiconductor plants have been approved, with a combined capacity to produce over 7 crore chips daily.

Challenges:

• While the "Make in India" initiative has seen significant success, challenges remain in job creation and the growth of small and medium enterprises (SMEs).

Source: https://www.business-standard.com/economy/news/make-in-india-124092501064_1.html

Question: Which country is the second largest manufacturer of smart phones?

1. China
2. South Korea
3. India
4. USA

50 commonly used drugs found substandard, companies say products spurious, not theirs

The Central Drug Standards Control Organisation (CDSCO), India's apex drug regulatory body, recently identified over 50 commonly prescribed drugs as substandard. These include medications for high blood pressure, acid reflux, and erectile dysfunction. The findings raise concerns over the quality of drugs available in the market, with certain batches found to be spurious or not meeting the required standards.

Key Findings:

• CDSCO's survey detected that various batches of drugs produced by leading pharmaceutical companies failed quality checks.
• Sun Pharmaceuticals: A batch of Pulmosil (Sildenafil injection) was found substandard, though the company claimed it was a spurious version, not manufactured by them.
• Glenmark Pharmaceuticals: A batch of Telma H (Telmisartan 40mg and Hydrochlorothiazide 12.5mg tablets IP), used for blood pressure control, was also found to be non-standard. Glenmark disputed the findings, asserting the batch in question was not produced by them.
• Alkem Health Science: A batch of Clavam 625 (Amoxicillin and Potassium Clavulanate tablets) also failed to meet regulatory standards.

Regulatory and Industry Response:

• Drug regulatory bodies, including CDSCO, regularly conduct random sampling to monitor and address any violations of Good Manufacturing Practices (GMP).
• Despite these findings, there hasn't been a notable increase in substandard drug samples. Regulatory efforts remain constant to ensure that manufacturing practices improve and prevent future violations.

Public Health Considerations:

• Authorities emphasized that the discovery of one substandard batch does not imply all drugs of that name are unsafe. Corrective actions are typically taken swiftly to prevent widespread public health issues.
• The government continues to maintain pressure on pharmaceutical companies to improve manufacturing standards and ensure the availability of safe and effective drugs.

Source: https://timesofindia.indiatimes.com/india/50-commonly-used-drugs-found-substandard-companies-say-products-spurious-not-theirs/articleshow/113679248.cms

Question: Which among the following is an antibiotic?

1. Paracetamol
2. Asprin
3. Amoxicillin
4. Ibuprofen